✦ LIBER ✦

Randomized Phase II Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin Plus Cyclophosphamide in Axillary Node-Positive Breast Cancer

✍ Scribed by Tejani, M.A.; Goldstein, L.J.

Book ID: 122495218
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 52 KB
Volume: 20
Category: Article
ISSN: 1043-321X
DOI: 10.1016/S1043-321X(09)79287-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II Feasibility Trial of Dose-Den

A Phase II Feasibility Trial of Dose-Dense Docetaxel Followed by Doxorubicin/Cyclophosphamide as Adjuvant or Neoadjuvant Treatment for Women with Node-Positive or High-Risk Node-Negative Breast Cancer

✍ Denise A. Yardley; Howard A. Burris III; Cindy P. Farley; John H. Barton; Nancy 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 109 KB

Phase I/II Trial of Adjuvant Dose-Dense

Phase I/II Trial of Adjuvant Dose-Dense Docetaxel/Epirubicin/Cyclophosphamide (TEC) in Stage II and III Breast Cancer

✍ Susan Burdette-Radoux; Marie E. Wood; Julie J. Olin; Rebecca S. Laughlin; Abigai 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 463 KB

Toxicity of Dose-Dense Docetaxel Followe

Toxicity of Dose-Dense Docetaxel Followed by Doxorubicin with Cyclophosphamide as Adjuvant Therapy for Breast Cancer in a Phase II Study

✍ Rosemary Lambert-Falls; Susan Modugno 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 110 KB

Adjuvant docetaxel, doxorubicin, and cyc

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

✍ John R Mackey; Miguel Martin; Tadeusz Pienkowski; Janusz Rolski; Jean-Paul Guast 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 340 KB

A randomized feasibility/phase II study

A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

✍ S. Margolin; L. Carlsson; M. Hellstrom; P. Karlsson; E. Lidbrink; B. Linderholm; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Prognostic and Predictive Value of Tumor

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

✍ Loi, S.; Sirtaine, N.; Piette, F.; Salgado, R.; Viale, G.; Van Eenoo, F.; Rouas, 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 313 KB